Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371991 | 1.00 | ALDH1A1 (0.36) | ALDH1A1BCHEERBB2EPHA2KDR | |
| SCHEMBL17104730 | 1.00 | ALDH1A1 (0.36) | ALDH1A1BCHEERBB2EPHA2KDR | |
| SCHEMBL907185 | 0.91 | ALDH1A1 (0.41) | ALDH1A1BCHEERBB2EPHA2KDR | |
| SCHEMBL907186 | 0.91 | ALDH1A1 (0.41) | ALDH1A1BCHEERBB2EPHA2KDR | |
| SCHEMBL7151311 | 0.91 | ALDH1A1 (0.41) | ALDH1A1BCHEERBB2EPHA2KDR | |
| SCHEMBL7153071 | 0.91 | ALDH1A1 (0.41) | ALDH1A1BCHEERBB2EPHA2KDR | |
| SCHEMBL13689312 | 0.91 | ALDH1A1 (0.41) | ALDH1A1BCHEERBB2EPHA2KDR | |
| SCHEMBL17616927 | 0.82 | ALDH1A1 (0.42) | ALDH1A1BCHEMAPT | |
| SCHEMBL17252165 | 0.82 | ALDH1A1 (0.42) | ALDH1A1BCHEMAPT | |
| SCHEMBL20613593 | 0.82 | ALDH1A1 (0.42) | ALDH1A1BCHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-1521747-B1 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | SYMPHONY EVOLUTION INC (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1773826-A2 | C-MET MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1521747-A4 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1521747-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004006846-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885BCHE 997/4885ERBB2 56/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885BCHE 997/4885ERBB2 56/4885 |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | ALDH1A1 3477/4885BCHE 3185/4885ERBB2 5/4885 |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | ALDH1A1 3597/4885BCHE 3367/4885ERBB2 6/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | ALDH1A1 3477/4885BCHE 3185/4885ERBB2 5/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885BCHE 997/4885ERBB2 56/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | ALDH1A1 2072/4885BCHE 997/4885ERBB2 56/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ALDH1A1 2578/4885BCHE 1371/4885ERBB2 109/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885BCHE 997/4885ERBB2 56/4885 |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | ALDH1A1 2382/4885BCHE 1450/4885ERBB2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.